BRKR
NASDAQ · Life Sciences Tools & Services
Bruker Corp
$41.93
+0.89 (+2.17%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 3.42B | 3.06B | 2.13B | 1.92B | 2.28B |
| Net Income | 114.94M | 92.65M | 265.94M | 220.32M | 272.46M |
| EPS | — | — | — | — | — |
| Profit Margin | 3.4% | 3.2% | 12.5% | 11.5% | 12.0% |
| Rev Growth | +11.7% | +11.7% | +17.3% | +23.7% | -3.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 1.72B | 1.72B | 859.40M | 752.51M | 754.20M |
| Total Equity | 1.46B | 1.46B | 2.63B | 2.63B | 2.39B |
| D/E Ratio | 1.18 | 1.18 | 0.33 | 0.29 | 0.32 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 412.22M | 350.71M | 426.56M | 370.66M | 419.03M |
| Free Cash Flow | — | — | 235.03M | 246.46M | 325.34M |